CONFIDENTIAL Amendment #2 to the Letter of Agreement between SmithKline Beecham Corporation and Quest Diagnostics Incorporated
EX-10.6 7 c54355_ex10-6.htm c54355_ex10-6.htm -- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing
Exhibit 10.6
CONFIDENTIAL
Amendment #2 to the
Letter of Agreement between
SmithKline Beecham Corporation and
Quest Diagnostics Incorporated
| 1. | The purpose of this Amendment #2 to the Letter of Agreement effective January 1, 2008 between SmithKline Beecham Corporation d/b/a GlaxoSmithKline and Quest Diagnostics Incorporated (hereinafter the “LOA”) is to extend the term referenced in section 2 of the LOA to the earlier of (i) June 30, 2008, or (ii) the full execution of a new comprehensive Global Clinical Trials Agreement. |
| 2. | All other terms and conditions of the LOA shall remain in full force and effect. |
| 3. | The parties hereto agree to this Amendment #2 to the LOA by their authorized signatures below. |
| SMITHKLINE BEECHAM CORPORATION | QUEST DIAGNOSTICS INCORPORATED | ||
| /s/ Paula M. Russella | /s/ Daniel P. Megronigle | ||
| Paula M. Russella | Daniel P. Megronigle | ||
| Sourcing Group Manager | Executive Director, Sales & Marketing | ||
| May 21, 2008 | May 15, 2008 | ||
| Date | Date | ||
